Patents Assigned to TargetRx, Inc.
-
Publication number: 20210070758Abstract: A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation and use thereof are disclosed. In particular, a compound of formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. As a selective irreversible inhibitor of Bruton's tyrosine kinase, the described compound can be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers.Type: ApplicationFiled: August 16, 2017Publication date: March 11, 2021Applicant: Shenzhen TargetRx. Inc.Inventors: Yihan Wang, Qingfeng Xing
-
Patent number: 10875853Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.Type: GrantFiled: January 19, 2018Date of Patent: December 29, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
-
Publication number: 20200377473Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.Type: ApplicationFiled: January 19, 2018Publication date: December 3, 2020Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan WANG, Jiuyang ZHAO, Yixin AI
-
Patent number: 10851062Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: GrantFiled: November 18, 2019Date of Patent: December 1, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 10780082Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition including the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.Type: GrantFiled: September 10, 2019Date of Patent: September 22, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Huanyin Li
-
Publication number: 20200190036Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: ApplicationFiled: November 18, 2019Publication date: June 18, 2020Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 10543199Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.Type: GrantFiled: February 23, 2017Date of Patent: January 28, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Huanyin Li
-
Patent number: 10519193Abstract: Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).Type: GrantFiled: December 29, 2016Date of Patent: December 31, 2019Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20190382374Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.Type: ApplicationFiled: January 19, 2018Publication date: December 19, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan WANG, Jiuyang ZHAO, Yixin AI
-
Patent number: 10479767Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: GrantFiled: December 13, 2016Date of Patent: November 19, 2019Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
SUBSTITUTED BORIC ACID COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND APPLICATION THEREOF
Publication number: 20190263835Abstract: A substituted boric acid compound, a pharmaceutical composition including the same, and an application thereof. The substituted boric acid compound is a compound represented by formula (I), or a crystal form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The boric acid compound has proteasome inhibitory activity, good pharmacodynamic/pharmacokinetic performance, good applicability, and high safety, and can be used for preparing drugs for treating diseases related to proteasomes.Type: ApplicationFiled: July 24, 2017Publication date: August 29, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Jiuyang Zhao -
Publication number: 20190152954Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.Type: ApplicationFiled: January 24, 2019Publication date: May 23, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
-
Publication number: 20190092733Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: ApplicationFiled: December 13, 2016Publication date: March 28, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20190060292Abstract: A macrocycle represented by formula (I) and a pharmaceutical composition comprising the macrocycle, or a crystalline form, pharmaceutically acceptable salt, hydrate or solvent compound, stereoisomer, prodrug, or isotopic variant of the macrocycle. The macrocycle and the composition thereof inhibit a protein kinase.Type: ApplicationFiled: February 23, 2017Publication date: February 28, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Huanyin Li
-
Publication number: 20190040098Abstract: Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).Type: ApplicationFiled: December 29, 2016Publication date: February 7, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 7958000Abstract: A method and system for analyzing a “detail” (the use of promotional materials in combination with a sales pitch), measures the effectiveness of a sales presentation and its ability to drive market share through a standardized, quantitative evaluation of the entire sale presentation and its related components. The method includes administering a two, different surveys. The first survey, the Detail Performance Monitor survey, comprises an “in the field” test of how respondents are responding to various marketing strategies by tracking subsequent behavioral data of the respondents and comparing the behavioral data to the survey results. The second survey, the Detail Assessment survey, comprises an “in the lab” test of how various marketing strategies affect respondent attitude towards a product by comparing respondent attitude before and after presentation of a simulated “detail” that represents the marketing strategy.Type: GrantFiled: May 26, 2006Date of Patent: June 7, 2011Assignee: TargetRX, Inc.Inventors: Michael J. Luby, Patrick J. Howie, Braden C. Parker, Jeffrey A. Kozloff, Jason T. Crook, Daniel J. Cohen, Adam R. Priest
-
Patent number: 7080027Abstract: A method and system for analyzing a “detail” (the use of promotional materials in combination with a sales pitch), measures the effectiveness of a sales presentation and its ability to drive market share through a standardized, quantitative evaluation of the entire sale presentation and its related components. The method includes administering a two, different surveys. The first survey, the Detail Performance Monitor survey, comprises an “in the field” test of how respondents are responding to various marketing strategies by tracking subsequent behavioral data of the respondents and comparing the behavioral data to the survey results. The second survey, the Detail Assessment survey, comprises an “in the lab” test of how various marketing strategies affect respondent attitude towards a product by comparing respondent attitude before and after presentation of a simulated “detail” that represents the marketing strategy.Type: GrantFiled: April 17, 2003Date of Patent: July 18, 2006Assignee: TargetRx, Inc.Inventors: Michael J. Luby, Patrick J. Howie, Braden C. Parker, Jeffrey A. Kozloff, Jason T. Crook, Daniel J. Cohen, Adam R. Priest
-
Publication number: 20040210471Abstract: A method and system for analyzing a “detail” (the use of promotional materials in combination with a sales pitch), measures the effectiveness of a sales presentation and its ability to drive market share through a standardized, quantitative evaluation of the entire sale presentation and its related components. The method includes administering a two, different surveys. The first survey, the Detail Performance Monitor survey, comprises an “in the field” test of how respondents are responding to various marketing strategies by tracking subsequent behavioral data of the respondents and comparing the behavioral data to the survey results. The second survey, the Detail Assessment survey, comprises an “in the lab” test of how various marketing strategies affect respondent attitude towards a product by comparing respondent attitude before and after presentation of a simulated “detail” that represents the marketing strategy.Type: ApplicationFiled: April 17, 2003Publication date: October 21, 2004Applicant: TargetRx,Inc.Inventors: Michael J. Luby, Patrick J. Howie, Braden C. Parker, Jeffrey A. Kozloff, Jason T. Crook, Daniel J. Cohen, Adam R. Priest